Emcure Pharma IPO Details
Emcure Pharmaceuticals is gearing up for its IPO launch tomorrow, with expectations of raising Rs.1,952 crore through a combination of fresh issue and an offer for sale (OFS). Notably, Namita Thapar, a well-known investor from Shark Tank India and a key member of Emcure Pharmaceuticals' promoter group, stands to generate approximately Rs.127.87 crore by selling around 12.68 lakh shares in the OFS at a price range of Rs.960 to Rs.1,008 per share. Thapar, who currently holds 3.5% of the company's shares, acquired her stake at a weighted average price of Rs.3.44 per share. Additionally, she has been reappointed as a Whole-Time Director for another five years, effective July 28, 2024, following approvals from the board and shareholders.
Alongside Thapar, other promoters such as Satish Ramanlal Mehta, Sunil Rajanikant Mehta, and Samit Satish Mehta, as well as several entities including BC Investments IV and individuals like Pushpa Rajnikant Mehta and Kamini Sunil Mehta, will also participate in the OFS, collectively contributing to the Rs.1,151 crore offer for sale component of the IPO. The funds raised from this IPO will primarily be used to repay existing loans and for general corporate purposes, as outlined in the company's prospectus.
Emcure Pharmaceuticals is recognized for its robust presence in the pharmaceutical industry, specializing in the development, manufacturing, and global distribution of a diverse range of pharmaceutical products across multiple therapeutic areas. Their portfolio includes injectables, biotherapeutics, and oral medications, catering to markets in over 70 countries, with significant operations in Europe, Canada, and India.
The IPO is being managed by Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited as the book running lead managers, with Link Intime India Private Ltd. serving as the registrar. The grey market premium for Emcure Pharmaceuticals' IPO currently stands at +290, indicating a strong investor appetite with shares trading significantly above the IPO price band. This suggests an anticipated listing price around Rs.1,298 per share, reflecting a 28.77% premium over the upper end of the IPO price range, underscoring investor confidence and market optimism towards the company's prospects.